• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

SARS-CoV-2 spike-dependent platelet activation in COVID-19 vaccine-induced thrombocytopenia.

作者信息

Appelbaum Jacob, Arnold Donald M, Kelton John G, Gernsheimer Terry, Jevtic Stefan D, Ivetic Nikola, Smith James W, Nazy Ishac

机构信息

Division of Hematology, Department of Medicine, University of Washington School of Medicine, Seattle, WA; and.

Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.

出版信息

Blood Adv. 2022 Apr 12;6(7):2250-2253. doi: 10.1182/bloodadvances.2021005050.

DOI:10.1182/bloodadvances.2021005050
PMID:34724709
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8563079/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd5e/9006288/b45a8e643639/advancesADV2021005050f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd5e/9006288/71a4e6051e2c/advancesADV2021005050f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd5e/9006288/b45a8e643639/advancesADV2021005050f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd5e/9006288/71a4e6051e2c/advancesADV2021005050f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd5e/9006288/b45a8e643639/advancesADV2021005050f2.jpg

相似文献

1
SARS-CoV-2 spike-dependent platelet activation in COVID-19 vaccine-induced thrombocytopenia.新型冠状病毒肺炎疫苗诱导的血小板减少症中严重急性呼吸综合征冠状病毒2刺突蛋白依赖性血小板活化
Blood Adv. 2022 Apr 12;6(7):2250-2253. doi: 10.1182/bloodadvances.2021005050.
2
The role of anti-platelet factor 4 antibodies and platelet activation tests in patients with vaccine-induced immune thrombotic thrombocytopenia: Brief report on a comparison of the laboratory diagnosis and literature review.抗血小板因子 4 抗体和血小板活化试验在疫苗诱导免疫性血栓性血小板减少症患者中的作用：实验室诊断比较及文献复习简要报告。
Clin Chim Acta. 2022 Apr 1;529:42-45. doi: 10.1016/j.cca.2022.02.003. Epub 2022 Feb 12.
3
Inflammation and Platelet Activation After COVID-19 Vaccines - Possible Mechanisms Behind Vaccine-Induced Immune Thrombocytopenia and Thrombosis.新冠病毒疫苗接种后的炎症和血小板活化 - 疫苗诱导免疫性血小板减少症和血栓形成的可能机制。
Front Immunol. 2021 Nov 23;12:779453. doi: 10.3389/fimmu.2021.779453. eCollection 2021.
4
VITT with inactivated SARS-CoV-2 vaccine - index case.接种过灭活 SARS-CoV-2 疫苗的 VITT - 首例病例。
Hum Vaccin Immunother. 2022 Dec 31;18(1):2036556. doi: 10.1080/21645515.2022.2036556. Epub 2022 Mar 7.
5
COVID-19: SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia.新型冠状病毒肺炎：严重急性呼吸综合征冠状病毒2疫苗诱导的免疫性血栓性血小板减少症
Hamostaseologie. 2021 Jun;41(3):179-182. doi: 10.1055/a-1369-3488. Epub 2021 Jun 30.
6
SARS-CoV-2 vaccine-induced prothrombotic immune thrombocytopenia: Promoting awareness to improve patient-doctor trust.严重急性呼吸综合征冠状病毒2型疫苗诱导的血栓形成性免疫性血小板减少症：提高认识以增强医患信任。
J Med Virol. 2021 Oct;93(10):5721-5723. doi: 10.1002/jmv.27176. Epub 2021 Jul 11.
7
Vaccine-Inducted Thrombotic Thrombocytopenia and Covid-19 Vaccines: Case Series.疫苗诱导的血栓性血小板减少症与新冠病毒疫苗：病例系列。
Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2022 Apr 22;43(1):49-55. doi: 10.2478/prilozi-2022-0005.
8
[Severe thrombocytopenia after COVID-19 mRNA vaccination].[新冠病毒mRNA疫苗接种后出现严重血小板减少症]
Rinsho Ketsueki. 2021;62(12):1684-1687. doi: 10.11406/rinketsu.62.1684.
9
Unusual Fever, Headache, and Abdominal Pain in a Healthy Woman.一名健康女性出现的异常发热、头痛和腹痛
Gastroenterology. 2021 Nov;161(5):1387-1389. doi: 10.1053/j.gastro.2021.07.039. Epub 2021 Jul 31.
10
SARS-CoV-2-related and Covid-19 vaccine-induced thromboembolic events: A comparative review.SARS-CoV-2 相关及新冠病毒疫苗诱导的血栓栓塞事件：比较综述。
Rev Med Virol. 2022 Jul;32(4):e2327. doi: 10.1002/rmv.2327. Epub 2022 Feb 3.

引用本文的文献

1
VITT Pathophysiology: An Update.疫苗诱导的血栓性血小板减少症（VITT）的病理生理学：最新进展
Vaccines (Basel). 2025 Jun 17;13(6):650. doi: 10.3390/vaccines13060650.
2
Platelet activating histone/antihistone IgG complexes in anti-PF4 negative thrombosis and thrombocytopenia syndrome.抗PF4阴性血栓形成和血小板减少综合征中的血小板活化组蛋白/抗组蛋白IgG复合物
Blood Adv. 2025 Apr 3. doi: 10.1182/bloodadvances.2024015076.
3
Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases, in Patients with Cardiac Issues, and in the Healthy Population.

本文引用的文献

1
Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects.康复的 COVID-19 患者体内抗 SARS-CoV-2 抗体的特征。
Viruses. 2021 Apr 16;13(4):697. doi: 10.3390/v13040697.
2
Platelet-activating immune complexes identified in critically ill COVID-19 patients suspected of heparin-induced thrombocytopenia.在疑似肝素诱导血小板减少症的危重症 COVID-19 患者中鉴定出血小板激活免疫复合物。
J Thromb Haemost. 2021 May;19(5):1342-1347. doi: 10.1111/jth.15283. Epub 2021 Mar 14.
3
Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination.
新型冠状病毒肺炎疫苗在自身免疫性疾病患者、有心脏问题的患者及健康人群中的安全性
Pathogens. 2023 Feb 2;12(2):233. doi: 10.3390/pathogens12020233.
4
Immune thrombocytopenia and COVID-19 vaccination: Outcomes and comparisons to prepandemic patients.免疫性血小板减少症与新冠病毒疫苗接种：结果及与疫情前患者的比较
Res Pract Thromb Haemost. 2023 Jan;7(1):100009. doi: 10.1016/j.rpth.2022.100009. Epub 2022 Dec 13.
5
Understanding the Pharmacology of COVID-19 mRNA Vaccines: Playing Dice with the Spike?了解 COVID-19 mRNA 疫苗的药理学：与刺突蛋白玩骰子？
Int J Mol Sci. 2022 Sep 17;23(18):10881. doi: 10.3390/ijms231810881.
6
The spike hypothesis in vaccine-induced adverse effects: questions and answers.疫苗引起不良反应的刺突假说：问题与解答。
Trends Mol Med. 2022 Oct;28(10):797-799. doi: 10.1016/j.molmed.2022.07.009. Epub 2022 Sep 12.
7
SARS-CoV-2 spike protein inhibits megalin-mediated albumin endocytosis in proximal tubule epithelial cells.SARS-CoV-2 刺突蛋白抑制近端肾小管上皮细胞中 megalin 介导的白蛋白内吞作用。
Biochim Biophys Acta Mol Basis Dis. 2022 Dec 1;1868(12):166496. doi: 10.1016/j.bbadis.2022.166496. Epub 2022 Jul 18.
8
Antibodies against Platelet Factor 4 and Their Associated Pathologies: From HIT/HITT to Spontaneous HIT-Like Syndrome, to COVID-19, to VITT/TTS.抗血小板因子4抗体及其相关病理：从肝素诱导的血小板减少症/肝素诱导的血小板减少症和血栓形成，到自发性类肝素诱导的血小板减少症综合征，再到冠状病毒病，直至疫苗诱导的血小板减少症/血栓性血小板减少性紫癜
Antibodies (Basel). 2022 Jan 21;11(1):7. doi: 10.3390/antib11010007.
辉瑞和莫德纳新冠疫苗接种后出现的血小板减少症。
Am J Hematol. 2021 May 1;96(5):534-537. doi: 10.1002/ajh.26132. Epub 2021 Mar 9.
4
Antibody-induced procoagulant platelets in severe COVID-19 infection.严重 COVID-19 感染中的抗体诱导的促凝血小板。
Blood. 2021 Feb 25;137(8):1061-1071. doi: 10.1182/blood.2020008762.
5
A comparative study of platelet factor 4-enhanced platelet activation assays for the diagnosis of heparin-induced thrombocytopenia.血小板因子 4 增强的血小板激活试验用于肝素诱导的血小板减少症诊断的比较研究。
J Thromb Haemost. 2021 Apr;19(4):1096-1102. doi: 10.1111/jth.15233. Epub 2021 Feb 19.
6
Characterization of platelet factor 4 amino acids that bind pathogenic antibodies in heparin-induced thrombocytopenia.鉴定与肝素诱导的血小板减少症中致病性抗体结合的血小板因子 4 氨基酸。
J Thromb Haemost. 2019 Feb;17(2):389-399. doi: 10.1111/jth.14369.
7
Distinguishing between anti-platelet factor 4/heparin antibodies that can and cannot cause heparin-induced thrombocytopenia.区分能引起肝素诱导的血小板减少症和不能引起肝素诱导的血小板减少症的抗血小板因子 4/肝素抗体。
J Thromb Haemost. 2015 Oct;13(10):1900-7. doi: 10.1111/jth.13066. Epub 2015 Aug 29.
8
Recommendations for standardization of laboratory testing for drug-induced immune thrombocytopenia: communication from the SSC of the ISTH.药物性免疫性血小板减少症实验室检测标准化建议：来自国际血栓与止血学会（ISTH）标准化委员会的沟通文件
J Thromb Haemost. 2015 Apr;13(4):676-8. doi: 10.1111/jth.12852. Epub 2015 Feb 17.
9
A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia.药物诱导免疫性血小板减少症的实验室检测的系统评价。
J Thromb Haemost. 2013 Jan;11(1):169-76. doi: 10.1111/jth.12052.
10
A 14-year study of heparin-induced thrombocytopenia.一项关于肝素诱导的血小板减少症的14年研究。
Am J Med. 1996 Nov;101(5):502-7. doi: 10.1016/s0002-9343(96)00258-6.